|
|
| (86 intermediate revisions by 4 users not shown) |
| Line 1: |
Line 1: |
| {{DrugProjectFormSinglePage
| | #redirect [[Captopril]] |
| |genericName=generic name
| |
| |indication=a list of indications, separated by commas.
| |
| |hasBlackBoxWarning=Yes
| |
| |adverseReactions=a list of adverse reactions, separated by commas.
| |
| |blackBoxWarningTitle=Warning Title
| |
| |blackBoxWarningBody=<i><span style="color:#FF0000;">Condition Name:</span></i> (Content)
| |
| |fdaLIADAdult======Hypertension=====
| |
|
| |
|
| Captopril tablets, USP are indicated for the treatment of [[hypertension]].
| | [[Category: Cardiovascular Drugs]] |
| | | [[Category: Drug]] |
| In using captopril, consideration should be given to the risk of [[neutropenia]]/[[agranulocytosis]].
| | [[Category:ACE inhibitors]] |
| | |
| Captopril may be used as initial therapy for patients with normal renal function, in whom the risk is relatively low. In patients with [[impaired renal function]], particularly those with [[collagen vascular disease]], captopril should be reserved for [[hypertensive]]s who have either developed unacceptable side effects on other drugs, or have failed to respond satisfactorily to drug combinations.
| |
| | |
| Captopril is effective alone and in combination with other antihypertensive agents, especially [[thiazide]]-type [[diuretics]]. The [[blood pressure]] lowering effects of captopril and [[thiazides]] are approximately additive.
| |
| | |
| ======Heart Failure======
| |
| | |
| * Dosing Information
| |
| | |
| :* (Dosage) | |
| | |
| Captopril tablets, USP are indicated in the treatment of [[congestive heart failure]] usually in combination with [[diuretics]] and [[digitalis]]. The beneficial effect of captopril in [[heart failure]] does not require the presence of [[digitalis]], however, most controlled clinical trial experience with captopril has been in patients receiving [[digitalis]], as well as [[diuretic]] treatment.
| |
| | |
| ======Left Ventricular Dysfunction After Myocardial Infarction======
| |
| | |
| * Dosing Information
| |
| | |
| :* (Dosage)
| |
| | |
| Captopril tablets, USP are indicated to improve survival following [[myocardial infarction]] in clinically stable patients with [[left ventricular dysfunction]] manifested as an [[ejection fraction]] ≤40% and to reduce the incidence of overt [[heart failure]] and subsequent hospitalizations for [[congestive heart failure]] in these patients.
| |
| | |
| ======Diabetic Nephropathy======
| |
| | |
| * Dosing Information
| |
| | |
| :* (Dosage) | |
| | |
| Captopril tablets, USP are indicated for the treatment of [[diabetic nephropathy]] ([[proteinuria]] >500 mg/day) in patients with [[type I insulin-dependent diabetes mellitus]] and [[retinopathy]]. Captopril decreases the rate of progression of [[renal insufficiency]] and development of serious adverse clinical outcomes (death or need for renal transplantation or dialysis).
| |
| | |
| In considering use of captopril, it should be noted that in controlled trials [[ACE inhibitors]] have an effect on blood pressure that is less in black patients than in non-blacks. In addition, ACE inhibitors (for which adequate data are available) cause a higher rate of [[angioedema]] in black than in non-black patients.
| |
| | |
| |offLabelAdultGuideSupport======Condition 1=====
| |
| | |
| * Developed by: (Organisation)
| |
| | |
| * Class of Recommendation: (Class) (Link)
| |
| | |
| * Strength of Evidence: (Category A/B/C) (Link)
| |
| | |
| * Dosing Information/Recommendation
| |
| | |
| :* (Dosage)
| |
| | |
| =====Condition 2=====
| |
| | |
| * Developed by: (Organisation)
| |
| | |
| * Class of Recommendation: (Class) (Link)
| |
| | |
| * Strength of Evidence: (Category A/B/C) (Link)
| |
| | |
| * Dosing Information/Recommendation
| |
| | |
| :* (Dosage)
| |
| |offLabelAdultNoGuideSupport======Condition 1=====
| |
| | |
| * Dosing Information
| |
| | |
| :* (Dosage)
| |
| | |
| =====Condition 2=====
| |
| | |
| * Dosing Information
| |
| | |
| :* (Dosage)
| |
| | |
| =====Condition 3=====
| |
| | |
| * Dosing Information
| |
| | |
| :* (Dosage)
| |
| |fdaLIADPed
| |
| | |
| * Dosing Information
| |
| | |
| :* (Dosage)
| |
| | |
| |offLabelPedGuideSupport======Condition 1=====
| |
| | |
| * Developed by: (Organisation)
| |
| | |
| * Class of Recommendation: (Class) (Link)
| |
| | |
| * Strength of Evidence: (Category A/B/C) (Link)
| |
| | |
| * Dosing Information/Recommendation
| |
| | |
| :* (Dosage)
| |
| | |
| =====Condition 2=====
| |
| | |
| * Developed by: (Organisation)
| |
| | |
| * Class of Recommendation: (Class) (Link)
| |
| | |
| * Strength of Evidence: (Category A/B/C) (Link)
| |
| | |
| * Dosing Information/Recommendation
| |
| | |
| :* (Dosage)
| |
| |offLabelPedNoGuideSupport======Condition 1=====
| |
| | |
| * Dosing Information
| |
| | |
| :* (Dosage)
| |
| | |
| =====Condition 2=====
| |
| | |
| * Dosing Information
| |
| | |
| :* (Dosage)
| |
| | |
| =====Condition 3=====
| |
| | |
| * Dosing Information
| |
| | |
| :* (Dosage)
| |
| |contraindications=* Condition 1
| |
| * Condition 2
| |
| * Condition 3
| |
| * Condition 4
| |
| * Condition 5
| |
| |warnings======Conidition 1=====
| |
| | |
| (Description)
| |
| | |
| =====Conidition 2=====
| |
| | |
| (Description)
| |
| | |
| =====Conidition 3=====
| |
| | |
| (Description)
| |
| |clinicalTrials=======Central Nervous System======
| |
| | |
| : (list/description of adverse reactions)
| |
| | |
| ======Cardiovascular======
| |
| | |
| : (list/description of adverse reactions)
| |
| | |
| ======Respiratory======
| |
| | |
| : (list/description of adverse reactions)
| |
| | |
| ======Gastrointestinal======
| |
| | |
| : (list/description of adverse reactions)
| |
| | |
| ======Hypersensitive Reactions======
| |
| | |
| : (list/description of adverse reactions)
| |
| | |
| ======Miscellaneous======
| |
| | |
| : (list/description of adverse reactions)
| |
| | |
| =====Condition 2=====
| |
| | |
| ======Central Nervous System======
| |
| | |
| : (list/description of adverse reactions)
| |
| | |
| ======Cardiovascular======
| |
| | |
| : (list/description of adverse reactions)
| |
| | |
| ======Respiratory======
| |
| | |
| : (list/description of adverse reactions)
| |
| | |
| ======Gastrointestinal======
| |
| | |
| : (list/description of adverse reactions)
| |
| | |
| ======Hypersensitive Reactions======
| |
| | |
| : (list/description of adverse reactions)
| |
| | |
| ======Miscellaneous======
| |
| | |
| : (list/description of adverse reactions)
| |
| |postmarketing=(Description)
| |
| |drugInteractions=* Drug 1
| |
| * Drug 2
| |
| * Drug 3
| |
| * Drug 4
| |
| * Drug 5
| |
| | |
| =====Drug 1=====
| |
| | |
| (Description)
| |
| | |
| =====Drug 2=====
| |
| | |
| (Description)
| |
| | |
| =====Drug 3=====
| |
| | |
| (Description)
| |
| | |
| =====Drug 4=====
| |
| | |
| (Description)
| |
| | |
| =====Drug 5=====
| |
| | |
| (Description)
| |
| |useInPregnancyFDA=(Description)
| |
| |useInPregnancyAUS=(Description)
| |
| |useInLaborDelivery=(Description)
| |
| |useInNursing=(Description)
| |
| |useInPed=(Description)
| |
| |useInGeri=(Description)
| |
| |useInGender=(Description)
| |
| |useInRace=(Description)
| |
| |useInRenalImpair=(Description)
| |
| |useInHepaticImpair=(Description)
| |
| |useInReproPotential=(Description)
| |
| |useInImmunocomp=(Description)
| |
| |administration=(Oral/Intravenous/etc)
| |
| |monitoring======Condition 1=====
| |
| | |
| (Description regarding monitoring, from ''Warnings'' section)
| |
| | |
| =====Condition 2=====
| |
| | |
| (Description regarding monitoring, from ''Warnings'' section)
| |
| | |
| =====Condition 3=====
| |
| | |
| (Description regarding monitoring, from ''Warnings'' section)
| |
| |IVCompat====Solution===
| |
| | |
| ====Compatible====
| |
| | |
| * Solution 1
| |
| * Solution 2
| |
| * Solution 3
| |
| | |
| ====Not Tested====
| |
| | |
| * Solution 1
| |
| * Solution 2
| |
| * Solution 3
| |
| | |
| ====Variable====
| |
| | |
| * Solution 1
| |
| * Solution 2
| |
| * Solution 3
| |
| | |
| ====Incompatible====
| |
| | |
| * Solution 1
| |
| * Solution 2
| |
| * Solution 3
| |
| | |
| ===Y-Site===
| |
| | |
| ====Compatible====
| |
| | |
| * Solution 1
| |
| * Solution 2
| |
| * Solution 3
| |
| | |
| ====Not Tested====
| |
| | |
| * Solution 1
| |
| * Solution 2
| |
| * Solution 3
| |
| | |
| ====Variable====
| |
| | |
| * Solution 1
| |
| * Solution 2
| |
| * Solution 3
| |
| | |
| ====Incompatible====
| |
| | |
| * Solution 1
| |
| * Solution 2
| |
| * Solution 3
| |
| | |
| ===Admixture===
| |
| | |
| ====Compatible====
| |
| | |
| * Solution 1
| |
| * Solution 2
| |
| * Solution 3
| |
| | |
| ====Not Tested====
| |
| | |
| * Solution 1
| |
| * Solution 2
| |
| * Solution 3
| |
| | |
| ====Variable====
| |
| | |
| * Solution 1
| |
| * Solution 2
| |
| * Solution 3
| |
| | |
| ====Incompatible====
| |
| | |
| * Solution 1
| |
| * Solution 2
| |
| * Solution 3
| |
| | |
| ===Syringe===
| |
| | |
| ====Compatible====
| |
| | |
| * Solution 1
| |
| * Solution 2
| |
| * Solution 3
| |
| | |
| ====Not Tested====
| |
| | |
| * Solution 1
| |
| * Solution 2
| |
| * Solution 3
| |
| | |
| ====Variable====
| |
| | |
| * Solution 1
| |
| * Solution 2
| |
| * Solution 3
| |
| | |
| ====Incompatible====
| |
| | |
| * Solution 1
| |
| * Solution 2
| |
| * Solution 3
| |
| | |
| ===TPN/TNA===
| |
| | |
| ====Compatible====
| |
| | |
| * Solution 1
| |
| * Solution 2
| |
| * Solution 3
| |
| | |
| ====Not Tested====
| |
| | |
| * Solution 1
| |
| * Solution 2
| |
| * Solution 3
| |
| | |
| ====Variable====
| |
| | |
| * Solution 1
| |
| * Solution 2
| |
| * Solution 3
| |
| | |
| ====Incompatible====
| |
| | |
| * Solution 1
| |
| * Solution 2
| |
| * Solution 3
| |
| |overdose====Acute Overdose===
| |
| | |
| ====Signs and Symptoms====
| |
| | |
| (Description)
| |
| | |
| ====Management====
| |
| | |
| (Description)
| |
| | |
| ===Chronic Overdose===
| |
| | |
| ====Signs and Symptoms====
| |
| | |
| (Description)
| |
| | |
| ====Management====
| |
| | |
| (Description)
| |
| |drugBox={{Drugbox2
| |
| | verifiedrevid =
| |
| | IUPAC_name =
| |
| | image =
| |
| | drug_name =
| |
| | |
| <!--Clinical data-->
| |
| | tradename =
| |
| | MedlinePlus =
| |
| | licence_US =
| |
| | pregnancy_AU =
| |
| | pregnancy_US =
| |
| | legal_status =
| |
| | routes_of_administration =
| |
| | |
| <!--Pharmacokinetic data-->
| |
| | bioavailability =
| |
| | metabolism =
| |
| | elimination_half-life =
| |
| | excretion =
| |
| | |
| <!--Identifiers-->
| |
| | CAS_number_Ref =
| |
| | CAS_number =
| |
| | ATC_prefix =
| |
| | ATC_suffix =
| |
| | PubChem =
| |
| | IUPHAR_ligand =
| |
| | DrugBank_Ref =
| |
| | DrugBank =
| |
| | ChemSpiderID_Ref =
| |
| | ChemSpiderID =
| |
| | UNII_Ref =
| |
| | UNII =
| |
| | KEGG_Ref =
| |
| | KEGG =
| |
| | ChEBI_Ref =
| |
| | ChEBI =
| |
| | ChEMBL_Ref =
| |
| | ChEMBL =
| |
| | |
| <!--Chemical data-->
| |
| | C= | H= | N= | O=
| |
| | molecular_weight =
| |
| | smiles =
| |
| | InChI =
| |
| | InChIKey =
| |
| | StdInChI_Ref =
| |
| | StdInChI =
| |
| | StdInChIKey_Ref =
| |
| | StdInChIKey =
| |
| | melting_point =
| |
| }}
| |
| |mechAction=(Description)
| |
| |structure=(Description with picture)
| |
| |PD=(Description)
| |
| |PK=(Description)
| |
| |nonClinToxic=(Description)
| |
| |clinicalStudies======Condition 1=====
| |
| | |
| (Description)
| |
| | |
| =====Condition 2=====
| |
| | |
| (Description)
| |
| | |
| =====Condition 3=====
| |
| | |
| (Description)
| |
| |howSupplied=(Description)
| |
| |fdaPatientInfo=(Patient Counseling Information)
| |
| |nlmPatientInfo=(Link to patient information page)
| |
| |lookAlike=* (Paired Confused Name 1a) — (Paired Confused Name 1b)
| |
| * (Paired Confused Name 2a) — (Paired Confused Name 2b)
| |
| * (Paired Confused Name 3a) — (Paired Confused Name 3b)
| |
| |drugShortage=Drug Shortage
| |
| }}
| |